Article

Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring

Centre Medico Psychologique B, CHU G. Montpied, BP39 63003, Clermont-Ferrand Cedex 3, France.
Clinical Chemistry (Impact Factor: 7.91). 10/2001; 47(9):1719-21.
Source: PubMed
Download full-text

Full-text

Available from: P.-M. Llorca, Mar 29, 2014
    • "However, atypical psychotropics, also called " second-generation antipsychotics, " such as risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole , and clozapine, were introduced in the 1990s and have demonstrated a more advantageous profile of activity.Zhang et al. (2008)reviewed the bioanalytical methods for the determination of antipsychotic drugs in biological samples and pointed out that, due to their hydrophobic and involatile properties, such drugs are good candidates for separation using reversed-phase HPLC. The determination of olanzapine, an atypical antipsychotic drug, was carried out by HPLC-DAD byLlorca et al. (2001). The procedure involved a three-step LLE for sample preparation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This is a review of the literature regarding high-performance liquid chromatography-diode array detection (HPLC-DAD) procedures for the detection and determination of several categories of central nervous system–acting drugs in blood, plasma, or serum samples. Psychiatric and neurological drugs, such as antidepressants, benzodiazepines, antipsychotics, antiepileptics, and antiparkinsonians, have been included because of their relevance to therapeutic drug monitoring and systematic toxicological analysis. Articles published between 2000 and January 2012 have been taken into consideration. This review has focused on methodological approaches, sample pretreatment techniques, and other practical aspects.
    No preview · Article · Jan 2014 · Critical Reviews in Analytical Chemistry
  • Source

    Full-text · Article · Jan 2004 · Clinical Chemistry
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of new "atypical" antipsychotic agents, which are safer than classical neuroleptics and also active against the negative symptoms and neurocognitive deficits caused by the illness, has produced a significant advancement in the treatment of schizophrenia. The atypical (or "second generation") antipsychotics have several therapeutical properties in common, however they can significantly differ with regard to clinical potency and side effects. The main features regarding pharmacodynamics, pharmacokinetics and pharmacological interactions of the most important atypical antipsychotics, namely clozapine, olanzapine, quetiapine and risperidone, are treated herein. Several analytical methods available for the therapeutic drug monitoring of these drugs are also presented, as well as the novel formulations, which can notably improve the therapy of schizophrenia. Other very recent atypical agents, such as ziprasidone, aripiprazole, iloperidone, sertindole and zotepine will also be briefly described.
    No preview · Article · Mar 2004 · Current Medicinal Chemistry
Show more